Vanguard Group Inc. Has $15.93 Million Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Vanguard Group Inc. increased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 3.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,860,508 shares of the company’s stock after acquiring an additional 92,791 shares during the period. Vanguard Group Inc. owned about 0.06% of 4D Molecular Therapeutics worth $15,933,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Barclays PLC raised its holdings in 4D Molecular Therapeutics by 141.0% during the third quarter. Barclays PLC now owns 114,848 shares of the company’s stock valued at $1,241,000 after buying an additional 67,202 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of 4D Molecular Therapeutics by 5.3% during the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock valued at $409,000 after acquiring an additional 3,675 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of 4D Molecular Therapeutics by 139.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,354 shares of the company’s stock valued at $364,000 after purchasing an additional 38,031 shares during the period. State Street Corp lifted its position in 4D Molecular Therapeutics by 1.8% during the 3rd quarter. State Street Corp now owns 2,116,508 shares of the company’s stock worth $22,879,000 after acquiring an additional 37,232 shares during the last quarter. Finally, Proficio Capital Partners LLC lifted its position in shares of 4D Molecular Therapeutics by 100.0% during the 4th quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company’s stock worth $111,000 after purchasing an additional 10,000 shares during the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

FDMT opened at $3.06 on Friday. The firm has a market cap of $141.68 million, a PE ratio of -1.07 and a beta of 2.89. The firm’s fifty day moving average is $3.80 and its two-hundred day moving average is $5.94. 4D Molecular Therapeutics, Inc. has a twelve month low of $2.24 and a twelve month high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10). Equities analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on FDMT. Leerink Partners decreased their price target on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. Bank of America dropped their price objective on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Morgan Stanley decreased their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research report on Monday, January 13th. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $26.71.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.